Brief: Sensorion Reports Positive Efficacy Data From Sens-401 Phase 2A Clinical Study

Sensorion SA

05/07/2023 06:32

July 5 (Reuters) - Sensorion SA  ALSEN.PA :
    * SENSORION REPORTS POSITIVE EFFICACY DATA FROM SENS-401
PHASE 2A
CLINICAL STUDY
    * POSITIVE PRELIMINARY DATA SHOWED SENS-401 HAS A CLINICALLY
SIGNIFICANT EFFECT ON PRESERVATION OF RESIDUAL HEARING AFTER
COCHLEAR IMPLANTATION IN ALL ADULT PATIENTS TREATED SO FAR
    * DATA TO BE DETAILED AT A WEBINAR TODAY WEDNESDAY, JULY 5,
2023,
    * PATIENTS START TREATMENT WITH SENS-401 7 DAYS BEFORE
IMPLANTATION AND CONTINUE TO RECEIVE SENS-401 FOR A FURTHER 42
DAYS.
    * DATA UNVEILED TODAY SHOWS THAT STUDY ALSO ASSESSED A
NUMBER OF
SECONDARY ENDPOINTS, INCLUDING CHANGE OF HEARING THRESHOLD FROM
BASELINE TO END OF TREATMENT PERIOD IN IMPLANTED EAR AT SEVERAL
FREQUENCIES
    * FURTHER ANALYSIS SUGGESTS SENS-401 TREATED PATIENTS
DEMONSTRATED
PRESERVATION OF 21 DB OF THEIR RESIDUAL HEARING COMPARED TO
CONTROL GROUP SIX WEEKS AFTER COCHLEAR IMPLANTATION AT 500 HZ

Source text for Eikon:  ID:nBw3JbLcba 
Further company coverage:  ALSEN.PA 

 (Gdansk Newsroom)
 ((gdansk.newsroom@thomsonreuters.com; +48 58 7696600;))